Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 65Terminated 49Recruiting 27Active not recruiting 23Withdrawn 6Unknown 6Not yet recruiting 3Suspended 1Approved for marketing 1

Sponsor Class

OTHER 4NIH 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 1

Interventions

Paclitaxel 5Gemcitabine 3Nivolumab 2Injections 2E 7107 2Docetaxel 2Carboplatin 2Antibodies, Monoclonal 2130-nm albumin-bound paclitaxel 2venetoclax 1trastuzumab biosimilar HLX02 1taxane 1spartalizumab 1resiniferatoxin 1poly(I).poly(c12,U) 1pegamotecan 1palbociclib 1lenvatinib 1imisopasem manganese 1icotinib 1gusacitinib 1famitinib 1eniluracil 1dabrafenib 1cyclo-tetrakis(bis(1-phenyl-3-methyl-4-benzoylpyrazolon-5-ato)mu-oxotitanium(IV)) 1cobimetinib 1brincidofovir 1ammonium trichloro(dioxoethylene-O,O'-)tellurate 1aldesleukin 1abivertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × INDUSTRY × Azacitidine × Clear all
NCT04485052 2023-10-23

Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1/2 Suspended
222 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡